PharmaBoardroom

Diabetes in Asia & the need for region-specific research Dr Juliana Chan, one of Asia's leading endocrinologists, is also the founding director of GemVCare Limited, a company that provides data to medical professionals to advise patients on diabetes prevention, diagnosis, and treatment based on genetic profiling. In conversation, she discusses: 🔬 Some of the key differences in how diabetes manifests in Asian versus European populations and the importance of region-specific research 🕵♀️ Why early detection of diabetes, and stratifying patients into subtypes using biomarkers and algorithms ensures that they receive the right drug at the right time 🏃♀️ The importance of a holistic approach to diabetes management, combining medication with lifestyle changes, patient education, and team-based care to achieve better health outcomes. Read more at: https://lnkd.in/dkQjmGME  

Mexico: New government, new approach to healthcare? As Mexico prepares to welcome a new president, Hector Valle of leading Mexican think tank Fundación Mexicana para la Salud A.C. (FUNSALUD) casts his eye over the country's evolving healthcare landscape in terms of both progress made in addressing access gaps and how demographic shifts present new challenges. In conversation with PharmaBoardroom's Mary Carmen Luna Matuk and Patrick Burton Valle explains how FUNSALUD's four 'P's model (Predictive, Preventive, Personalized, Participatory) aims to leverage genetic insights and personalized medicine to improve health outcomes; outlines why innovative funding mechanisms and digitalisation are crucial to system sustainability; and emphasises the need for a fact-driven, scientific approach to governance.   Get the lowdown at: https://lnkd.in/dTNiWmCr

Exclusive Download - InFocus: The Future of HIV As the global HIV community gathers in Munich for the 25th International AIDS Conference, PharmaBoardroom is delighted to present a new special report for download - InFocus: The Future of HIV. Tremendous scientific and social advances have transformed HIV/AIDS from a death sentence to a manageable chronic condition for many. However, the disease still kills 650,000 people every year. Formidable societal, legal, and economic obstacles still stand in the way of the ultimate goal of complete eradication. This dedicated InFocus, bringing together key stakeholders – including leading physicians, researchers, activists, and pharmaceutical industry sponsors – strives to understand the achievements, shortfalls, and contradictions in the war against AIDS. From the transformed treatment paradigm to upcoming scientific breakthroughs, public policy progress, and revolutionised market access, this report sheds light on the immense steps forward that have been made over the past 40 years; some of the most pressing current challenges facing people living with HIV; and the causes for optimism – as well as concern – for their future. Featuring the insights of: Bettina Bauer, Gilead Sciences Linda-Gail Bekker, Desmond Tutu Health Foundation Carl Dieffenbach, National Institute of Allergy and Infectious Diseases (NIAID) Emily Kainne Dokubo, MD, MPH, PEPFAR Charles Gore, Medicines Patent Pool Lenias Hwenda, medicines for africa (mfa) Jayasree Iyer, Access to Medicine Foundation Flavia Kyomukama, International Alliance of Patients' Organizations (IAPO) Tom Lau & Xia Jin, Immuno Cure Birgit Poniatowski, International AIDS Society Bruce Richman, Prevention Access Campaign Johan Vekemans, IAVI Mitchell Warren, AVAC José M. Zuniga, International Association of Providers of AIDS Care Download your copy today at: https://lnkd.in/dxeFkTkt

New Mexico GMs, 'OnePlus' regulation in Hong Kong, the state of Chinese biotech, India Long Read...this week on PharmaBoardroom ⏐ Leadership in LatAm ⏐ Get to know the new Mexico country managers for Pfizer, MSD, Roche, Sanofi and Gilead Sciences https://lnkd.in/d_uzgGJA ⏐ HK Regulatory Upgrades ⏐ Hong Kong recently enacted the “OnePlus” mechanism, which allows for the approval of new drugs if they have been approved in only one reference country (rather than two). This is a big win for innovative pharma, as Sabrina, so kuen Chan of The Hong Kong Association of the Pharmaceutical Industry explains https://lnkd.in/dWeXfmS3 ⏐ The Long Read ⏐India: Demography, Democracy and Growth https://lnkd.in/d7bcFq4d ⏐ Chinese Biotech ⏐Since we last spoke to Transcenta's Xueming Qian, the company has listed on Hong Kong Exchanges and Clearing Limited (HKEX) and advanced its first-line gastric cancer treatment into phase III trials. Qian expands on this progress and weighs in on the state of Chinese biotech today more broadly https://lnkd.in/dz3JJkUq

A Fresh Start for Ipsen in China In conversation, Ipsen China General Manager Guillaume Delmotte talks us through the affiliate's strategic transformation, including moving headquarters to Shanghai, in line with the global shift from a consumer healthcare company to a leading player in specialty care, particularly in oncology and rare diseases. Delmotte also outlines his people-centric leadership style, building a high-performing, motivated, and purpose-driven team and creating a collaborative work environment. He also highlights the challenges of patient access and affordability in China, noting the disparities in co-payment systems and the need for better physician education, while praising the country's improved regulatory environment. Read more at: https://lnkd.in/ecU5qU-E

Unpacking Singaporean pharma regulations PharmaBoardroom has partnered with Benjamin Gaw (吴永灿) of Drew & Napier LLC, one of Singapore's leading law firms, to create The Pharma Legal Handbook: Singapore. This is a comprehensive rundown of everything you need to know about the country's pharma market, from Regulation to Pricing, Clinical and Preclinical Trials, Marketing, Manufacturing, Trademarks, Patents, and more! Get your copy of the updated 2024 edition now at: https://lnkd.in/dsUh_6Pc

NHS Reform Front & Centre for New UK Health Secretary The newly elected UK government’s Secretary of State for Health and Social Care Rt. Hon. Wes Streeting MP has a full plate of challenges ahead. Britain’s NHS (National Health Service) is plagued with a chronic lack of funding, staffing crunches and backlogs, while the country’s life sciences sector is seemingly in decline. Streeting has prioritised an urgent review of the NHS and potentially swingeing reforms to ensure that the system – free at the point of care to all users – remains in place for current and future generations. Read more at: https://lnkd.in/dCgiu2NM

Expert insights from the frontline of HIV research and activism A leading voice in the global fight against HIV, Professor Linda-Gail Bekker works across both scientific research and activism. As CEO and founder of the Desmond Tutu Health Foundation, Prof Bekker has helped change the course of the HIV/AIDS epidemic in South Africa. Her organisation has brought the latest HIV treatments and prevention - often through novel means and against a backdrop of stigma and discrimination - to the country's most vulnerable populations for 30 years. In conversation with PharmaBoardroom, she outlines the massive steps forward that have been made in the HIV field; the sometimes tortuous road still to travel to ensure equitable access to the latest technologies for all; and some of the most promising research projects in the pipeline - notably the plan to develop an #HIVvaccine in Africa, and for Africa, over the next five years. Read the full interview at: https://lnkd.in/ddH8hQRA

Brazilian Pharma in 2024: 5 Gamechanging Trends to Watch With the largest public healthcare system in the world, Latin America’s biggest pharma market, its leading regulatory body, and a huge and diverse population, Brazil is a strategic destination for both regional and global pharma. Click the link for five trends to watch from this dynamic nation in 2024 and beyond. https://lnkd.in/gPz4d62s

Empowering Women, Strengthening Communities: Fernando Fogarin on Organon's Mission Drawing on an industry track record of over 25 years, Fernando Fogarin has recently become the strategic project lead for emerging markets at women's health specialist Organon. He shares his priorities and the particularities of the Mexican market, discussing the positive impact of the country’s upcoming biosimilars reform; Organon’s efforts to address the issue of teenage pregnancy; and how the firm’s Mexican manufacturing facility aligns with the region’s nearshoring trend. Read more at: https://lnkd.in/g5W8N5rK Mary Carmen Luna Matuk